google-site-verification: googlec7193c3de77668c9.html

NHS patients in England can have life-saving heart drug tafamidis

About 1,500 people in England with ATTR-CM could now be eligible for the treatment.

This rare heart condition typically starts to show in adulthood and gets worse over time as the heart tissue thickens and stiffens.

Its symptoms include:

  • shortness of breath

  • palpitations and abnormal heart rhythms

  • ankle swelling, fatigue, fainting and chest pain

Ultimately, it can cause heart failure.

Prof Simon Ray, national clinical director for heart disease at NHS England, said: ”A first of its kind, tafamidis will give those living with this rare progressive condition new hope.

“This pioneering drug is just one example of the NHS delivering on its commitment to ensure patients across the country have access to the latest and most effective treatments to help significantly improve their quality of life.”

The list price for a packet of 30 capsules of the drug is about £10,000, but Pfizer has a commercial agreement for NHS use which will be less, although the cost has not been made public.


Source link

Advertisements

See also  Choosing an IVF embryo is uncertain: A new dish design could improve what labs see

Check Also

Lab-on-a-chip predicts which cancer treatments may work for pediatric acute lymphoblastic leukemia

[ Device schematic and experimental workflow. Credit: Nature Biomedical Engineering (2026). DOI: 10.1038/s41551-026-01818-0 More than …

Aging people with autism more likely to have Parkinson’s disease symptoms

[ Credit: winter visual from Pexels Older people with autism are more likely to develop …

Controlled inhalation of thin air may alleviate Parkinson’s symptoms

[ In the 39-minute experiment, volunteers wore masks that alternated between four six-minute cycles of …

Leave a Reply

Available for Amazon Prime